Physician profile
Richard A Hall
NPI 1134178353
$2,238.13
in general payments reported to CMS, 2019-2025
31 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Adolescent Medicine (Internal Medicine) provider received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $180 · 2021: $426 · 2022: $185 · 2023: $277 · 2024: $591 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Midmark Corporation | $426.12 | 2021 | |
| Supernus Pharmaceuticals, INC. | $378.42 | 2024 | Qelbree |
| Glaxosmithkline, LLC. | $257.50 | 2019-2024 | Bexsero, Shingrix |
| Novo Nordisk INC | $158.81 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $108.03 | 2019-2025 | |
| Abbvie INC. | $106.47 | 2019-2024 | |
| Allergan, INC. | $73.98 | 2019-2020 | |
| Gilead Sciences, INC. | $70.83 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $68.80 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Corium, LLC | $63.77 | 2022-2025 | Azstarys |
| Astrazeneca Pharmaceuticals Lp | $57.93 | 2019-2025 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $57.70 | 2019-2023 | Austedo Xr |
| Lilly USA, LLC | $48.56 | 2022-2023 | Mounjaro, Jardiance |
| Axsome Therapeutics, INC. | $28.78 | 2023 | Auvelity |
| Novartis Pharmaceuticals Corporation | $28.55 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $28.38 | 2024 | |
| Seqirus USA INC | $26.91 | 2025 | Fluad, Flucelvax |
| Neurocrine Biosciences, INC. | $25.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.21 | 2019-2020 | |
| Tris Pharma INC | $24.77 | 2023 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $20.84 | 2024 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $20.25 | 2025 | Spravato |
| Sage Therapeutics, LLC | $20.06 | 2024 | |
| Neuronetics, INC. | $17.85 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.81 | 2022 | |
| Abbott Laboratories | $17.49 | 2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.38 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.78 | 2020 | |
| Hologic Sales and Service, LLC | $13.72 | 2022 | |
| Exact Sciences Corporation | $13.00 | 2023 | Cologuard Collection Kit |
| Bardy Diagnostics, INC. | $3.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.